Live webcast with Walter Klemp, Chairman and Chief Executive
Officer, on Thursday, March
28th at 12:00 PM
ET
HOUSTON,
March 27,
2024 /PRNewswire/ -- Moleculin Biotech, Inc.,
(Nasdaq: MBRX) (Moleculin or the Company), a clinical stage
pharmaceutical company with a broad portfolio of drug candidates
targeting hard-to-treat tumors and viruses, today announced that it
will present at the Virtual Investor Lunch Break: The Moleculin
Opportunity event on Thursday, March
28, 2024 at 12:00 PM ET.
As part of the event, Walter Klemp, Chairman and Chief Executive
Officer of Moleculin, will provide a corporate overview, business
outlook, and discuss the Moleculin opportunity.
A live video webcast of the event will be
available on the Events page under the Investors section
of the Company's website (moleculin.com). A webcast replay will be
available two hours following the live event and will be accessible
for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company with a growing pipeline, including Phase 2
clinical programs, for hard-to-treat tumors and viruses. The
Company's lead program, Annamycin is a next-generation
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity. Annamycin is currently in
development for the treatment of relapsed or refractory acute
myeloid leukemia (AML) and soft tissue sarcoma (STS) lung
metastases.
Additionally, the Company is developing WP1066,
an Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of viruses, as well as cancer
indications including brain tumors, pancreatic and other
cancers.
For more information about the Company, please
visit www.moleculin.com and connect on Twitter,
LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-participate-in-the-virtual-investor-lunch-break-the-moleculin-opportunity-302100348.html
SOURCE Moleculin Biotech, Inc.